Who are oxytocin nasal spray's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oxytocin (Low dose), VIP, Cerebrolysin infusion, Placebo then intranasal oxytocin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxytocin-nasal-spray.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

oxytocin nasal spray — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

oxytocin nasal spray (oxytocin nasal spray) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuropeptide. Area: Psychiatry/Neurology.

marketed Neuropeptide Oxytocin receptor (OXTR) Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

oxytocin nasal spray (oxytocin nasal spray) — University of Electronic Science and Technology of China. Oxytocin nasal spray delivers the neuropeptide oxytocin directly to the brain via intranasal administration to modulate social bonding, trust, and emotional processing.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
oxytocin nasal spray TARGET	oxytocin nasal spray	University of Electronic Science and Technology of China	marketed	Neuropeptide	Oxytocin receptor (OXTR)
Oxytocin (Low dose)	Oxytocin (Low dose)	The University of Texas Medical Branch, Galveston	marketed	Neuropeptide agonist	Oxytocin receptor (OXTR)
VIP	VIP	Danish Headache Center	marketed	Neuropeptide agonist	VIP receptor (VPAC1/VPAC2)
Cerebrolysin infusion	Cerebrolysin infusion	Clinical Institute of the Brain, Russia	marketed	Neuropeptide mixture
Placebo then intranasal oxytocin	Placebo then intranasal oxytocin	MacDonald, Kai, M.D.	marketed	Neuropeptide	Oxytocin receptor (OXTR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuropeptide class)

MacDonald, Kai, M.D. · 1 drug in this class
University of Electronic Science and Technology of China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oxytocin nasal spray — Competitive Intelligence Brief. https://druglandscape.com/ci/oxytocin-nasal-spray. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab